Live Breaking News & Updates on Medicine Ventures

Stay updated with breaking news from Medicine ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Biological E to begin phase 3 trials for COVID-19 vaccine


Biological E to begin phase 3 trials for COVID-19 vaccine
By Yunus Y Lasania|   Published: 24th April 2021 5:24 pm IST
Hyderabad: Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE) today announced that it has successfully completed the phase I/II clinical trials of its COVID-19 subunit vaccine candidate in India. The company has also received approval to start phase III clinical trials from the Central Drugs Standard Control Organization (CDSCO) – Subject Expert Committee (SEC).
The phase III clinical study to be conducted in 15 sites across India, and will evaluate the Immunogenicity and Safety of Biological E’s SARS-CoV-2 COVID-19 vaccine for protection against COVID-19 disease in about 1268 healthy subjects in the age range of 18 to 80 years. It is intended to be part of a larger global Phase III study, the company stated. ....

United States , Andhra Pradesh , Baylor College Of Medicine , Mahima Datla , Peter Hotez , Baylor College Of Medicine Ventures , National School Of Tropical Medicine At Baylor , Central Drugs Standard Control Organization , Coalition For Epidemic Preparedness Innovations , Dynavax Technologies Corporation Nasdaq , Biotechnology Industry Research Assistance Council , Texas Children Hospital Center , Vaccine Development , Be Limited , Expert Committee , Subject Expert Committee , Managing Director , Texas Children , Hospital Center , Baylor College , Dynavax Technologies Corporation , Epidemic Preparedness Innovations , Receptor Binding Domain , Spike Protein , Latin America , National School ,